VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), announces today that it has completed the sale of (AAGP™) as a vital tool to protect delicate cells in the process of utilizing stem cells, to treat disease and injury. This development will enable the Company to ramp up sales of the unique AAGP™ family of molecules to the medical research community. This community includes major pharmaceutical corporations, universities, foundations, private laboratories, and government agencies.
